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found that unaffected mucosa of UC patients showed no 
difference to healed mucosa of UC patients in remission 
and to mucosa of healthy controls. They concluded that 
the reason for a reduced protein production is very likely 
the inflammatory process per se.
 Although not having received the same level of atten-
tion, efflux transporters now share their fate with the   -
defensins: a major role in the pathogenesis of IBD has 
been ruled out. In a recent publication in  Gut , Lisa Simms 
 [13] and her Australian colleagues had taken the   -defen-
sin story apart in a similar examination of a large series 
of more than 100 patients and controls with Crohn’s dis-
ease or healthy guts. They showed that surface epithelial 
cells loss as a consequence of tissue damage by inflam-
mation seems to be the main reason for the reduced pro-
tein expression of   -defensins in patients with Crohn’s 
disease. Gutmann and Simms have taught us that IBDs 
are more than an efflux transporter or defensin deficien-
cy syndrome.
 
 In their paper, Heike Gutmann  [1] and her colleagues 
from Basel, Switzerland, nicely tell the story of the rise 
and fall of a suspected candidate in inflammatory bowel 
disease (IBD) pathogenesis by demonstrating that the ef-
flux transporters BCRP (breast cancer resistance pro-
tein) and P-gp (P-glycoprotein) play no major role in the 
pathogenesis of ulcerative colitis (UC).
 Among other organs important for uptake and elimi-
nation of toxic substances, the intestine expresses BCRP 
and P-gp in the apical membrane of the enterocytes  [2–6] . 
Previous genetic studies have reported that the P-gp and 
BCRP production is down-regulated in patients with ac-
tive UC  [7–10] and data indicated that their genetic locus 
is associated with a susceptibility for UC  [11, 12] . How-
ever, previous studies did not differentiate between the 
transporter expression in inflamed or unaffected mucosa 
and did not take into account whether the UC patients 
took anti-inflammatory medication. Therefore, Gut-
mann et al.  [1] evaluated transporter expression in both 
unaffected and inflamed mucosa of patients with active 
UC, in drug-naive and treated patients with UC and com-
pared the results to transporter expression in healthy 
subjects. They confirmed that P-gp and BCRP produc-
tion is significantly reduced in the inflamed mucosa of 
treated and untreated patients with active UC, but they 
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